US20070043103A1 - Novel metod for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof - Google Patents
Novel metod for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof Download PDFInfo
- Publication number
- US20070043103A1 US20070043103A1 US10/570,566 US57056604A US2007043103A1 US 20070043103 A1 US20070043103 A1 US 20070043103A1 US 57056604 A US57056604 A US 57056604A US 2007043103 A1 US2007043103 A1 US 2007043103A1
- Authority
- US
- United States
- Prior art keywords
- formula
- compound
- group
- synthesis
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 title claims abstract description 12
- 229960002582 perindopril Drugs 0.000 title claims abstract description 11
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 9
- 238000003786 synthesis reaction Methods 0.000 title claims abstract description 9
- 150000003839 salts Chemical class 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 10
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 238000010511 deprotection reaction Methods 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- -1 p-toluenesulphonyloxy, methanesulphonyloxy Chemical group 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 239000011736 potassium bicarbonate Substances 0.000 claims description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 239000010948 rhodium Substances 0.000 claims description 2
- 229910052703 rhodium Inorganic materials 0.000 claims description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- UCASZFYRYYFGHP-HARLFGEKSA-N benzyl (2s)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,4,5,6,7-hexahydroindole-2-carboxylate Chemical compound O=C([C@H]1N(C2=C(CCCC2)C1)C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)OCC1=CC=CC=C1 UCASZFYRYYFGHP-HARLFGEKSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- YTCLWENQKZZDTK-ZFEISSKQSA-N CCC[C@H](N[C@@H](C)C(=O)N1C2=C(CCCC2)C[C@H]1C)C(=O)OCC.S.S Chemical compound CCC[C@H](N[C@@H](C)C(=O)N1C2=C(CCCC2)C[C@H]1C)C(=O)OCC.S.S YTCLWENQKZZDTK-ZFEISSKQSA-N 0.000 description 2
- XLMKRSWEGFGTTB-SSDOTTSWSA-N C[C@@H]1CC2=C(CCCC2)N1 Chemical compound C[C@@H]1CC2=C(CCCC2)N1 XLMKRSWEGFGTTB-SSDOTTSWSA-N 0.000 description 2
- BWKDMJGULLIOQW-RJUBDTSPSA-N C[C@H](N)C(=O)N1C2=C(CCCC2)C[C@H]1C.S Chemical compound C[C@H](N)C(=O)N1C2=C(CCCC2)C[C@H]1C.S BWKDMJGULLIOQW-RJUBDTSPSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- XJFFZPRSIPQLCY-MXLIJYGISA-N S.S.[H][C@@]12CCCC[C@]1([H])N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(=O)O)C2 Chemical compound S.S.[H][C@@]12CCCC[C@]1([H])N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(=O)O)C2 XJFFZPRSIPQLCY-MXLIJYGISA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- PKOSSINKGUYOOH-JXFKEZNVSA-N benzyl (2s)-1-[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]-2,3,4,5,6,7-hexahydroindole-2-carboxylate Chemical compound O=C([C@H]1N(C2=C(CCCC2)C1)C(=O)[C@@H](NC(=O)OC(C)(C)C)C)OCC1=CC=CC=C1 PKOSSINKGUYOOH-JXFKEZNVSA-N 0.000 description 2
- HDCVJBXIISZAHS-GUYCJALGSA-N benzyl (2s)-1-[(2s)-2-aminopropanoyl]-2,3,4,5,6,7-hexahydroindole-2-carboxylate Chemical compound O=C([C@H]1N(C2=C(CCCC2)C1)C(=O)[C@@H](N)C)OCC1=CC=CC=C1 HDCVJBXIISZAHS-GUYCJALGSA-N 0.000 description 2
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- NRAMCLOSUDJHAH-YUMQZZPRSA-N (2s)-2-[[(2s)-1-ethoxy-1-oxopropan-2-yl]amino]pentanoic acid Chemical compound CCC[C@@H](C(O)=O)N[C@@H](C)C(=O)OCC NRAMCLOSUDJHAH-YUMQZZPRSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- HZPKNSYIDSNZKW-SSDOTTSWSA-N CCC[C@@H](C)C(=O)OCC Chemical compound CCC[C@@H](C)C(=O)OCC HZPKNSYIDSNZKW-SSDOTTSWSA-N 0.000 description 1
- 0 C[C@](C(N([C@@](C1)C(O*)=O)C2=C1CCCC2)=O)N Chemical compound C[C@](C(N([C@@](C1)C(O*)=O)C2=C1CCCC2)=O)N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- XJFFZPRSIPQLCY-LQATVTLGSA-N S.S.[H][C@@]12CCCC[C@]1([H])N(C(=O)[C@H](C)N[C@H](CCC)C(=O)OCC)[C@H](C(=O)O)C2 Chemical compound S.S.[H][C@@]12CCCC[C@]1([H])N(C(=O)[C@H](C)N[C@H](CCC)C(=O)OCC)[C@H](C(=O)O)C2 XJFFZPRSIPQLCY-LQATVTLGSA-N 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FDMGPVBOWQRJCK-HNNXBMFYSA-N benzyl (2s)-2,3,4,5,6,7-hexahydro-1h-indole-2-carboxylate Chemical compound O=C([C@H]1NC2=C(CCCC2)C1)OCC1=CC=CC=C1 FDMGPVBOWQRJCK-HNNXBMFYSA-N 0.000 description 1
- ARGCRCXTJMQKNA-KKUMJFAQSA-N benzyl (2s,3as,7as)-2,3,3a,4,5,6,7,7a-octahydro-1h-indole-2-carboxylate Chemical compound O=C([C@H]1N[C@H]2CCCC[C@H]2C1)OCC1=CC=CC=C1 ARGCRCXTJMQKNA-KKUMJFAQSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- VLDADOIBISWPAB-CYBMUJFWSA-N ethyl (2r)-2-(4-methylphenyl)sulfonyloxypentanoate Chemical compound CCOC(=O)[C@@H](CCC)OS(=O)(=O)C1=CC=C(C)C=C1 VLDADOIBISWPAB-CYBMUJFWSA-N 0.000 description 1
- ZAOIIUSDMKVQJW-ZCFIWIBFSA-N ethyl (2r)-2-chloropentanoate Chemical compound CCC[C@@H](Cl)C(=O)OCC ZAOIIUSDMKVQJW-ZCFIWIBFSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- SDBQPOCLUYDXKE-YFKPBYRVSA-N tert-butyl n-[(2s)-1-chloro-1-oxopropan-2-yl]carbamate Chemical compound ClC(=O)[C@H](C)NC(=O)OC(C)(C)C SDBQPOCLUYDXKE-YFKPBYRVSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a process for the synthesis of perindopril of formula (I): and its pharmaceutically acceptable salts.
- angiotensin I converting enzyme or kininase II
- kininase II angiotensin I converting enzyme
- Patent specification EP 0 308 341 describes the industrial synthesis of perindopril by the coupling of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid benzyl ester with N-[(S)-1-carboxybutyl]-(S)-alanine ethyl ester, followed by deprotection of the carboxylic group of the heterocycle by catalytic hydrogenation.
- the present invention relates to a process for the synthesis of perindopril and its pharmaceutically acceptable salts which is characterised in that the compound of formula (II): wherein R 1 represents a hydrogen atom or a benzyl or linear or branched (C 1 -C 6 )alkyl group, is reacted with a compound of formula (III) having the S configuration: wherein X represents a halogen atom and R 2 represents a protecting group for the amino function, in the presence of a base, to yield, after deprotection of the amino function, a compound of formula (IV): wherein R 1 is as defined hereinbefore, which is reacted with a compound of formula (V): wherein G represents a chlorine, bromine or iodine atom or a p-toluenesulphonyloxy, methanesulphonyloxy or trifluoromethanesulphonyloxy group, in the presence of a base, to yield a compound of formula (I
- the groups tert-butoxycarbonyl and benzyl may be mentioned without implying any limitation.
- R 1 preferably represents a benzyl group.
- the protecting group for the amino function is preferably the tert-butoxycarbonyl group.
- organic amines such as triethylamine, pyridine, N-methylmorpholine or diisopropylethylamine
- mineral bases such as NaOH, KOH, Na 2 CO 3 , K 2 CO 3 , NaHCO 3 or KHCO 3 .
- Step A Benzyl (2S)-1- ⁇ (2S)-2-[(tert-butoxycarbonyl)amino]propionyl ⁇ -2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate
- Step B Benzyl (2S)-1- ⁇ (2S)-2-aminopropionyl ⁇ -2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate
- Step C Benzyl (2S)-1- ⁇ (2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl ⁇ -2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate
- Step D (2S,3aS,7aS)-1- ⁇ (2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl ⁇ -octahydro-1H-indole-2-carboxylic acid
- Step E (2S,3aS,7aS)-1- ⁇ (2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl ⁇ -octahydro-1H-indole-2-carboxylic acid tert-butylamine salt
- the precipitate obtained in the above Step (200 g) is dissolved in 2.8 litres of acetonitrile, and then 40 g of tert-butylamine and 0.4 litres of ethyl acetate are added.
- the suspension obtained is then refluxed until dissolution is complete, and the solution obtained is subsequently filtered hot and cooled, with stirring, to a temperature of from 15 to 20° C.
- the resulting precipitate is then filtered off, made into a paste again with acetonitrile, dried and then recrystallised from ethyl acetate to give the expected product in a yield of 95% and with an enantiomeric purity of 99%.
- Steps A and B Identical to Steps A and B of Example 1
- Step C Benzyl (2S)-1- ⁇ (2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl ⁇ -2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate
- Steps D and E Identical to Steps D and E of Example 1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
-
- Perindopril and its pharmaceutically acceptable salts, and more especially its tert-butylamine salt, have valuable pharmacological properties.
- Their principal property is that of inhibiting angiotensin I converting enzyme (or kininase II), which allows, on the one hand, prevention of the conversion of the decapeptide angiotensin I to the octapetide angiotensin II (a vasoconstrictor) and, on the other hand, prevention of the degradation of bradykinin (a vasodilator) to an inactive peptide.
- Those two actions contribute to the beneficial effects of perindopril in cardiovascular diseases, more especially in arterial hypertension and heart failure.
- Perindopril, its preparation and its use in therapeutics have been described in the European patent specification EP 0 049 658.
- In view of the pharmaceutical value of this compound, it has been important to be able to obtain it by an effective synthesis process, readily transposable to an industrial scale, that leads to perindopril in a good yield and with excellent purity starting from reasonably priced starting materials.
- Patent specification EP 0 308 341 describes the industrial synthesis of perindopril by the coupling of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid benzyl ester with N-[(S)-1-carboxybutyl]-(S)-alanine ethyl ester, followed by deprotection of the carboxylic group of the heterocycle by catalytic hydrogenation.
- The Applicant has now developed a new process for the synthesis of perindopril.
- More specifically, the present invention relates to a process for the synthesis of perindopril and its pharmaceutically acceptable salts which is characterised in that the compound of formula (II):
wherein R1 represents a hydrogen atom or a benzyl or linear or branched (C1-C6)alkyl group,
is reacted with a compound of formula (III) having the S configuration:
wherein X represents a halogen atom and R2 represents a protecting group for the amino function,
in the presence of a base,
to yield, after deprotection of the amino function, a compound of formula (IV):
wherein R1 is as defined hereinbefore,
which is reacted with a compound of formula (V):
wherein G represents a chlorine, bromine or iodine atom or a p-toluenesulphonyloxy, methanesulphonyloxy or trifluoromethanesulphonyloxy group,
in the presence of a base,
to yield a compound of formula (VI):
wherein R1 is as defined hereinbefore,
which is hydrogenated in the presence of a catalyst such as palladium, platinum, rhodium or nickel
to yield, after deprotection where necessary, the compound of formula (I). - Among the protecting groups for the amino function that can be used in the process of the present invention, the groups tert-butoxycarbonyl and benzyl may be mentioned without implying any limitation.
- R1 preferably represents a benzyl group. In that case the protecting group for the amino function is preferably the tert-butoxycarbonyl group.
- Among the bases that can be used in the reaction between the compounds of formulae (II) and (III) or between the compounds of formulae (IV) and (V) there may be mentioned, without implying any limitation, organic amines such as triethylamine, pyridine, N-methylmorpholine or diisopropylethylamine, and mineral bases such as NaOH, KOH, Na2CO3, K2CO3, NaHCO3 or KHCO3.
- Step A: Benzyl (2S)-1-{(2S)-2-[(tert-butoxycarbonyl)amino]propionyl}-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate
- Introduce 200 g of benzyl (2S)-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate and 1.5 litres of dichloromethane into a reactor, then bring the temperature of the reaction mixture to 0° C. and add 107 ml of triethylamine and then 162 g of (2S)-2-[(tert-butoxycarbonyl)amino]propionyl chloride. Subsequently, bring the mixture to ambient temperature. After stirring for 1 hour at that temperature, wash the mixture with water and then with a dilute acetic acid solution. The benzyl (2S)-1-{(2S)-2-[(tert-butoxycarbonyl)amino]propionyl}-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate solution so obtained is used as it is in the following Step.
- Step B: Benzyl (2S)-1-{(2S)-2-aminopropionyl}-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate
- Introduce the solution obtained in the above Step into a reactor, and then add 133 g of trifluoroacetic acid. After stirring for 1 hour 30 minutes at ambient temperature, wash the mixture with water and then with a saturated solution of sodium hydrogen carbonate and evaporate off the solvents to yield benzyl (2S)-1-{(2S)-2-aminopropionyl}-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate.
- Step C: Benzyl (2S)-1-{(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl}-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate
- Introduce into a reactor 200 g of the compound obtained in the above Step, 106 ml of diisopropylethylamine and 1.5 litres of tetrahydrofuran, and then 183 g of ethyl (2R)-2-p-toluenesulphonyloxy-pentanoate, and subsequently heat at 70° C. for 2 hours. After returning to ambient temperature, the mixture is washed with water and then concentrated to dryness. The residue is taken up in dichloromethane. A hydrochloric acid solution (2M) is added until a pH of about 7.5 is obtained. After decanting, the solvents are evaporated off to yield benzyl (2S)-1-{(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl}-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate.
- Step D: (2S,3aS,7aS)-1-{(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl}-octahydro-1H-indole-2-carboxylic acid
- Introduce 200 g of the compound obtained in the above Step, in solution in acetic acid, and then 5 g of 10% Pt/C into a hydrogenation vessel. Hydrogenate under a pressure of 5 bars at from 15 to 30° C. until the theoretical amount of hydrogen has been absorbed.
- Remove the catalyst by filtration and then cool to from 0 to 5° C. and collect the solid obtained by filtration. Wash the cake and dry it to constant weight.
- The (2S, 3aS, 7aS)-1-{(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl}octahydro-1H-indole-2-carboxylic acid is thereby obtained in a yield of 85% and with an enantiomeric purity of 98%.
- Step E: (2S,3aS,7aS)-1-{(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl}-octahydro-1H-indole-2-carboxylic acid tert-butylamine salt
- The precipitate obtained in the above Step (200 g) is dissolved in 2.8 litres of acetonitrile, and then 40 g of tert-butylamine and 0.4 litres of ethyl acetate are added.
- The suspension obtained is then refluxed until dissolution is complete, and the solution obtained is subsequently filtered hot and cooled, with stirring, to a temperature of from 15 to 20° C. The resulting precipitate is then filtered off, made into a paste again with acetonitrile, dried and then recrystallised from ethyl acetate to give the expected product in a yield of 95% and with an enantiomeric purity of 99%.
- Steps A and B: Identical to Steps A and B of Example 1
- Step C: Benzyl (2S)-1-{(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl}-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate
- Introduce 200 g of the compound obtained in the above Step, 106 ml of diisopropylethylamine and 1.5 litres of ethyl acetate into a reactor, followed by 165 g of ethyl (2R)-2-chloropentanoate, and then heat at 50° C. for 3 hours. After returning to ambient temperature, the mixture is washed with water and then concentrated to dryness. The residue is taken up in dichloromethane. A hydrochloric acid solution (2M) is added until a pH of about 7.5 is obtained. After decanting, the solvents are evaporated off to yield benzyl (2S)-1-{(2S)-2-[(1S)-1-(ethoxycarbonyl)butylamino]propionyl}-2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylate.
- Steps D and E: Identical to Steps D and E of Example 1
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03292131A EP1380590B1 (en) | 2003-08-29 | 2003-08-29 | Method for synthesis of perindopril and its pharmaceutically acceptable salts |
EP03292131.4 | 2003-08-29 | ||
PCT/FR2004/002196 WO2005023841A1 (en) | 2003-08-29 | 2004-08-27 | Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20070043103A1 true US20070043103A1 (en) | 2007-02-22 |
US7183308B1 US7183308B1 (en) | 2007-02-27 |
Family
ID=29724623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/570,566 Expired - Fee Related US7183308B1 (en) | 2003-08-29 | 2004-08-27 | Metod for the synthesis of perindopril and the pharmaceutically acceptable salts thereof |
Country Status (20)
Country | Link |
---|---|
US (1) | US7183308B1 (en) |
EP (1) | EP1380590B1 (en) |
JP (1) | JP4331205B2 (en) |
CN (1) | CN100395264C (en) |
AR (1) | AR045515A1 (en) |
AT (1) | ATE338766T1 (en) |
AU (1) | AU2004270427B2 (en) |
CY (1) | CY1105790T1 (en) |
DE (1) | DE60308102T2 (en) |
DK (1) | DK1380590T3 (en) |
EA (1) | EA008485B1 (en) |
ES (1) | ES2272922T3 (en) |
HK (1) | HK1096409A1 (en) |
MY (1) | MY139348A (en) |
NZ (1) | NZ545335A (en) |
PL (1) | PL211509B1 (en) |
PT (1) | PT1380590E (en) |
SI (1) | SI1380590T1 (en) |
WO (1) | WO2005023841A1 (en) |
ZA (1) | ZA200601428B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2252633T3 (en) * | 2003-08-29 | 2006-05-16 | Les Laboratoires Servier | NEW SYNTHESIS PROCEDURE OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE BASES. |
WO2005108365A1 (en) * | 2004-05-07 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Processes for the preparation of alpha polymorph of perindopril erbumine |
EP1987828A1 (en) | 2005-01-06 | 2008-11-05 | IPCA Laboratories Limited | salts of perindopril and their use in the therapy of hypertension |
WO2016178591A2 (en) | 2015-05-05 | 2016-11-10 | Gene Predit, Sa | Genetic markers and treatment of male obesity |
FR3050380B1 (en) | 2016-04-20 | 2020-07-10 | Les Laboratoires Servier | PHARMACEUTICAL COMPOSITION COMPRISING A BETA-BLOCKER, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSOR OR NSAID. |
CN108752259A (en) * | 2018-07-04 | 2018-11-06 | 南京方生和医药科技有限公司 | The preparation method of Perindopril raceme and its intermediate |
CN112047998B (en) * | 2020-09-07 | 2024-01-09 | 上海阿达玛斯试剂有限公司 | Preparation method of perindopril |
CN113980096A (en) * | 2021-11-29 | 2022-01-28 | 绍兴市上虞区武汉理工大学高等研究院 | Process for synthesizing ton-grade perindopril tert-butylamine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2503155A2 (en) * | 1980-10-02 | 1982-10-08 | Science Union & Cie | NOVEL SUBSTITUTED IMINO DIACIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS AN ENZYME INHIBITOR |
EP1319668B1 (en) * | 2003-03-12 | 2004-10-27 | Les Laboratoires Servier | Method for synthesis of (2S,3aS,7aS)-1-((S)-alanyl)-octahydro-1H-indole-2-carboxylic acid derivatives and use in the synthesis of perindopril |
SI1321471T1 (en) * | 2003-03-12 | 2005-08-31 | Servier Lab | |
ATE306496T1 (en) * | 2003-08-29 | 2005-10-15 | Servier Lab | METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
-
2003
- 2003-08-29 ES ES03292131T patent/ES2272922T3/en not_active Expired - Lifetime
- 2003-08-29 AT AT03292131T patent/ATE338766T1/en active
- 2003-08-29 PT PT03292131T patent/PT1380590E/en unknown
- 2003-08-29 DE DE60308102T patent/DE60308102T2/en not_active Expired - Lifetime
- 2003-08-29 DK DK03292131T patent/DK1380590T3/en active
- 2003-08-29 SI SI200330457T patent/SI1380590T1/en unknown
- 2003-08-29 EP EP03292131A patent/EP1380590B1/en not_active Expired - Lifetime
-
2004
- 2004-08-26 MY MYPI20043493A patent/MY139348A/en unknown
- 2004-08-27 PL PL379629A patent/PL211509B1/en unknown
- 2004-08-27 AU AU2004270427A patent/AU2004270427B2/en not_active Ceased
- 2004-08-27 EA EA200600456A patent/EA008485B1/en not_active IP Right Cessation
- 2004-08-27 ZA ZA200601428A patent/ZA200601428B/en unknown
- 2004-08-27 NZ NZ545335A patent/NZ545335A/en not_active IP Right Cessation
- 2004-08-27 AR ARP040103078A patent/AR045515A1/en not_active Application Discontinuation
- 2004-08-27 US US10/570,566 patent/US7183308B1/en not_active Expired - Fee Related
- 2004-08-27 CN CNB2004800241924A patent/CN100395264C/en not_active Expired - Fee Related
- 2004-08-27 WO PCT/FR2004/002196 patent/WO2005023841A1/en active Application Filing
- 2004-08-27 JP JP2006524394A patent/JP4331205B2/en not_active Expired - Fee Related
-
2006
- 2006-11-16 CY CY20061101672T patent/CY1105790T1/en unknown
-
2007
- 2007-02-01 HK HK07101187A patent/HK1096409A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PT1380590E (en) | 2006-12-29 |
JP2007526901A (en) | 2007-09-20 |
ES2272922T3 (en) | 2007-05-01 |
PL379629A1 (en) | 2006-10-30 |
PL211509B1 (en) | 2012-05-31 |
MY139348A (en) | 2009-09-30 |
AU2004270427A1 (en) | 2005-03-17 |
NZ545335A (en) | 2009-08-28 |
SI1380590T1 (en) | 2006-12-31 |
CY1105790T1 (en) | 2011-02-02 |
JP4331205B2 (en) | 2009-09-16 |
DE60308102D1 (en) | 2006-10-19 |
CN100395264C (en) | 2008-06-18 |
DE60308102T2 (en) | 2007-06-21 |
EA200600456A1 (en) | 2006-08-25 |
EP1380590A1 (en) | 2004-01-14 |
ZA200601428B (en) | 2007-05-30 |
US7183308B1 (en) | 2007-02-27 |
HK1096409A1 (en) | 2007-06-01 |
AR045515A1 (en) | 2005-11-02 |
ATE338766T1 (en) | 2006-09-15 |
EA008485B1 (en) | 2007-06-29 |
EP1380590B1 (en) | 2006-09-06 |
DK1380590T3 (en) | 2007-01-08 |
WO2005023841A1 (en) | 2005-03-17 |
CN1839147A (en) | 2006-09-27 |
AU2004270427B2 (en) | 2008-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7208607B1 (en) | Process for synthesis of perindopril and pharmaceutically acceptable salts thereof | |
US7220776B2 (en) | Method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof | |
US7179833B2 (en) | Method of synthesising perindopril and the pharmaceutically acceptable salts thereof | |
US7183308B1 (en) | Metod for the synthesis of perindopril and the pharmaceutically acceptable salts thereof | |
US7223872B2 (en) | Process for the synthesis of perindopril and its pharmaceutically acceptable salts | |
US7534896B2 (en) | Process for the synthesis of perindopril and its pharmaceutically acceptable salts | |
US7279583B2 (en) | Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof | |
JP4279871B2 (en) | Novel method for synthesizing (2S, 3AS, 7AS) -1-[(S) -alanyl] -octahydro-1H-indole-2-carboxylic acid derivatives and use thereof in perindopril synthesis | |
US7368580B2 (en) | Method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof | |
US7358372B2 (en) | Method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof | |
US7166633B2 (en) | Method for synthesising perindopril and the pharmaceutically acceptable salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LES LABORATOIRES SERVIER, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DUBUFFET, THIERRY;LECOUVE, JEAN-PIERRE;REEL/FRAME:018544/0645 Effective date: 20060207 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20190227 |